BRAIN Biotech secures landmark CRISPR-BMC nuclease patent for global genome editing
BRAIN Biotech has secured a key patent for its CRISPR-BMC nuclease technology. The European Patent Office approved the patent (EP4301852 B1), which took effect on March 18, 2026. It covers European Unitary Patent countries, Great Britain, Switzerland, the USA, and Japan.
The BMC® nuclease family is a proprietary CRISPR system developed by BRAIN Biotech. It shows high activity in both prokaryotic and eukaryotic organisms, enabling precise genome editing. The company uses this technology to optimise microbial strains for producing biomolecules.
Alexander Pelzer, Head of R&D, highlighted how CRISPR-BMC speeds up the development of production organisms. This helps customers improve strain development more efficiently. Adriaan Moelker, the CEO, added that the patent strengthens their ability to offer cost-effective, microorganism-based manufacturing processes. BRAIN Biotech has already licensed the technology to several companies. With the patent now in place, the firm plans to expand its licensing activities further. The company specialises in researching, developing, and producing specialty enzymes for the food and life sciences sectors.
The patent grant allows BRAIN Biotech to use and license CRISPR-BMC for both internal research and customer projects. This legal protection supports their position in the market for advanced genome-editing tools. The technology is expected to play a key role in future biomanufacturing processes.
